Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bromodomain testis-associated protein (BRDT)
- Target
- BRDT
- Molecular classification
- Transcription factor (chromatin-associated), Epigenetic reader protein, BET family protein (bromodomain and extra-terminal domain protein), Non-enzymatic BRD-containing protein
01
Overview
Bromodomain testis-associated protein (BRDT) is an epigenetic reader and transcriptional regulatory protein that specifically binds to acetylated histones via its two bromodomains (BD1 and BD2). It is almost exclusively expressed in the testis, where it serves as a master regulator of meiosis and post-meiotic genome repackaging during spermatogenesis. BRDT interprets histone acetylation signals to orchestrate testis-specific gene expression and chromatin rearrangement. Emerging evidence highlights its ectopic expression and functional roles in certain cancers, such as esophageal squamous cell carcinoma. BRDT is a member of the BET family, sharing high homology with related proteins BRD2, BRD3, and BRD4, and, like other BET proteins, is targeted by small-molecule inhibitors that disrupt its bromodomain-mediated interactions, providing a potential strategy for contraception and cancer therapy
- Other names
- BRDTBromodomain, testis-specific proteinBRD6CT9Cancer/testis antigen 9Bromodomain protein testis-associated
02
Mechanism of action
Competitive inhibition of acetyl-lysine binding in bromodomains (BD1 and BD2), preventing BRDT from recognizing acetylated histones and transcription factors Disruption of chromatin-dependent gene regulation and transcriptional activity in targeted cells
03
Biological functions
Regulation of gene transcriptionChromatin remodelingHistone acetylation recognitionMale germ cell differentiation and spermatogenesisGenome packaging in post-meiotic spermatidsRegulation of enhancer activity via interaction with transcriptional co-regulators
04
Disease associations
Cancer (including esophageal squamous cell carcinoma; possible role in other tumors)Male infertility (due to defects in spermatogenesis and chromatin packaging)Potential role in other developmental or transcription-related diseases
05
Safety considerations
Testis specificity: Drugs inhibiting BRDT may affect fertility (male contraception)Off-target BET inhibition (BRD2, BRD3, BRD4) may result in transcriptional dysregulation and toxicityPotential for impact on spermatogenesis and chromatin structure in developing germ cells
06
Interacting drugs
(+)-JQ1 (BET bromodomain inhibitor, inhibits BRDT and other BET proteins)
3 more in the full profile.
07
Biomarkers
BRDT protein expression (in testis tissue, selected cancers)Histone acetylation levels (e.g., H4K5ac, H4K8ac)Chromatin accessibility assays
Beyond the preview
Go deeper on Bromodomain testis-associated protein (BRDT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bromodomain testis-associated protein (BRDT).